MYELOMA MULTIPLE
Clinical trials for MYELOMA MULTIPLE explained in plain language.
Never miss a new study
Get alerted when new MYELOMA MULTIPLE trials appear
Sign up with your email to follow new studies for MYELOMA MULTIPLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a targeted drug combo save kidneys in myeloma patients?
Disease control OngoingThis study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can better improve kidney function in people newly diagnosed with multiple myeloma who also have kidney failure. About 74 adults will receive either the daratumumab combo or the usual…
Matched conditions: MYELOMA MULTIPLE
Phase: PHASE2 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New Shot-Based myeloma combo aims to simplify treatment for older patients
Disease control OngoingThis study tests a new way to give the drug isatuximab—as a quick shot under the skin instead of a long IV drip—for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. About 74 participants aged 65 and older will receive the shot along wi…
Matched conditions: MYELOMA MULTIPLE
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New cocktail of four drugs shows promise against bone marrow cancer
Disease control OngoingThis study tests a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if adding two extra drugs to standard maintenance therapy can …
Matched conditions: MYELOMA MULTIPLE
Phase: PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take aim at incurable blood cancer
Disease control OngoingThis early-stage trial tests whether a new gene therapy is safe for people with multiple myeloma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. About 35 adults a…
Matched conditions: MYELOMA MULTIPLE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:04 UTC